Commonly used diabetes drugs could lower the risk of cardiometabolic conditions but heighten the risk of gastrointestinal and ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Furthermore, there is a growing trend towards the adoption of technologically advanced solutions, such as digital health platforms and telemedicine, for diabetes management. Leveraging these ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...

A study by Washington University School of Medicine and the VA St. Louis Health Care System has found that GLP-1 drugs can have both health benefits and risks, including reduced risks of ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...